PMID-25904023 – HCG-Based Combination Therapy Spermatogenesis Recovery

PMID-25904023 – HCG-Based Combination Therapy Spermatogenesis Recovery

Wenker EP, Dupree JM, Langille GM, Kovac J, Ramasamy R, Lamb D, Mills JN, Lipshultz LI. The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use. J Sex Med. 2015;12(6):1334-1337.

Quick Reference

Property Value
PMID 25904023
DOI 10.1111/jsm.12890
Year 2015
Journal Journal of Sexual Medicine
Study Type Case Series
Evidence Level IV
Sample 66 men with testosterone-related azoospermia or severe oligospermia
Peptide(s) Studied HCG

Key Findings

  • 66 men presented with likely testosterone-related azoospermia or severe oligospermia
  • HCG-based combination therapy (HCG + clomiphene or HCG + FSH) was used for recovery
  • Spermatogenesis recovered in the majority of men within 6-12 months
  • Mean time to recovery of sperm in the ejaculate was approximately 4-6 months
  • HCG alone was sometimes insufficient; combination with clomiphene or FSH improved outcomes
  • Approximately 3 million US men take testosterone, many unaware of fertility impact

Study Design

Retrospective case series of 66 men treated for testosterone-induced azoospermia or severe oligospermia. Treatment protocols included HCG 3000 IU 3x/week, often combined with clomiphene citrate 25-50 mg daily or recombinant FSH.

Limitations

  • Retrospective case series design (no controls)
  • Variable treatment protocols across patients
  • Duration and dose of prior testosterone use varied considerably
  • Self-selection bias (men seeking fertility)
  • Single-center experience

Clinical Relevance

Demonstrates that testosterone-induced azoospermia is reversible in most men with HCG-based therapy. This is critically relevant for the estimated 3 million US men on TRT who may not have been counseled about fertility effects. The study supports HCG as the first-line agent for fertility recovery after testosterone use, often combined with other gonadotropins or SERMs.

Related

#research #case-series #HCG #evidence-level-IV